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treatment of non‑erosive 
reflux disease and dynamics 
of the esophageal microbiome: 
a prospective multicenter study
Chan Hyuk Park1, Seung In Seo2, Joon Sung Kim3, Sun Hyung Kang4, Beom Jin Kim5, 
Yoon Jin choi6,7, Hyo Joo Byun8,9, Jung‑Ho Yoon8,9 & Sang Kil Lee8,9*
Non‑erosive reflux disease (NERD) pathogenesis has not been thoroughly evaluated. Here, we 
assessed the response of patients with NERD to proton pump inhibitor (PPI) therapy; changes in the 
microbiome and biologic marker expression in the esophageal mucosa were also evaluated. Patients 
with NERD (n = 55) received esomeprazole (20 mg) for eight weeks. The treatment response was 
evaluated at baseline, week four, and week eight. Esophageal mucosal markers and oropharyngeal 
and esophageal microbiomes were analyzed in patients who underwent upper gastrointestinal 
endoscopy at screening (n = 18). Complete and partial response rates at week eight were 60.0% 
and 32.7% for heartburn, and 61.8% and 29.1% for regurgitation, respectively. The expressions 
of several inflammatory cytokines, including IL‑6, IL‑8, and NF‑κB, were decreased at week eight. 
Streptococcus, Haemophilus, Prevotella, Veillonella, Neisseria, and Granulicatella were prevalent 
regardless of the time‑point (baseline vs. week eight) and organ (oropharynx vs. esophagus). The 
overall composition of oropharyngeal and esophageal microbiomes showed significant difference 
(P = 0.004), which disappeared after PPI therapy. In conclusion, half‑dose PPI therapy for eight weeks 
could effectively control NERD symptoms. The expression of several inflammatory cytokines was 
reduced in the esophagus, and oropharyngeal and esophageal microbiomes in patients with NERD 
showed significant difference. However, the microbial compositions in the oropharynx and esophagus 
were not affected by PPI therapy in this study. Impact of PPI on the microbiome in patients with NERD 
should be more investigated in future studies.
Non-erosive reflux disease (NERD) is characterized by the presence of typical gastroesophageal reflux disease 
(GERD) symptoms, including heartburn and regurgitation, associated with pathological acid reflux but the 
absence of esophageal  erosion1,2. NERD presents in approximately 70% of patients with  GERD3,4. Acid-suppres-
sive therapy with proton pump inhibitors (PPIs) is a mainstay in the treatment of  NERD5,6. However, the thera-
peutic gain of PPIs in the treatment of NERD is relatively low, compared to the treatment of erosive  esophagitis7.
Recently, the assumption that NERD and erosive esophagitis represent one continuous disorder within the 
spectrum of GERD has been challenged because several studies demonstrated differences in the epidemiologi-
cal features, pathophysiological characteristics, as well as treatment responses of these  diseases3,8–10. NERD has 
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several differential pathogenic characteristics, including relatively low mucosal permeability, high visceral sen-
sitivity, and common psychological co-morbidity, compared to erosive  esophagitis11. Nevertheless, our under-
standing of the pathogenesis of NERD is still incomplete.
Recently, there have been attempts to identify the impact of the microbiome on the development of  GERD12. 
The influence of the microbiome on the development of digestive diseases is an emerging issue in gastroen-
terological research. We know that Helicobacter pylori infection is the most important cause of gastric cancer 
and peptic ulcer  diseases13. Additionally, Fusobacterium nucleatum, which is a periodontal bacteria that is also 
found in the intestine, has been suggested as a cause of colorectal  cancer14–16. Although this causal relationship 
has not been proven, recent studies demonstrated that several bacterial taxa, including Prevotella, Haemophilus, 
Neisseria, and Veillonella, are abundant in the esophagus of patients with  GERD17–19. Additionally, it has been 
shown that PPIs may be associated with the composition of the esophageal  microbiome19.
Until now, however, the esophageal microbiome in patients with NERD has not been investigated. To increase 
our understanding of NERD, we aimed to evaluate the treatment response to PPIs in patients with NERD and 
changes in their biologic marker expression and microbial composition before and after PPI therapy. We also 
compared the esophageal microbiome of the NERD patients with the oropharyngeal microbiome due to the tight 
regulatory interplay of these microbiomes with each other.
Results
Study participants and baseline characteristics. Sixty-six patients were assessed for eligibility for this 
study between October 2018 and August 2019. After excluding four patients with erosive esophagitis, 62 patients 
were enrolled in this study. Among them, seven patients withdrew their consent to participate in the study 
during the study period. As a result, the study finally included 55 patients, for whom treatment response was 
assessed. Of these 55 patients, 18 who had not been diagnosed with NERD, underwent upper gastrointestinal 
endoscopy for screening, and oral swab and esophageal mucosal biopsy were performed for these 18 patients.
Baseline characteristics of participants are demonstrated in Table 1. The mean age and proportion of males 
were 56.1 years and 41.8%, respectively. The proportion of patients with obesity was 38.2%. The frequency 
and duration were 4.8 /week and 22.5 months for heartburn and 3.6 /week and 23.6 months for regurgitation, 
Table 1.  Baseline characteristics of included patients. BMI, body mass index; SD, standard deviation.
Variable All patients Patients with biologic marker and microbial data
N 55 18
Age, year, mean ± SD 56.1 ± 15.3 56.8 ± 15.1
Sex, n (%)
Male 23 (41.8) 10 (55.6)
Female 32 (58.2) 8 (44.4)
BMI, mean ± SD 24.6 ± 3.8 22.8 ± 2.7
Obesity (BMI ≥ 25), n (%) 21 (38.2) 3 (16.7)
Smoking habit, n (%)
Never smoker 40 (72.7) 12 (66.7)
Former smoker 9 (16.4) 3 (16.7)
Current smoker 6 (10.9) 3 (16.7)
Alcohol consumption, n (%)
Never consumption 29 (52.7) 6 (33.3)
Former consumption 3 (5.5) 3 (16.7)
Current consumption 23 (41.8) 9 (50.0)
Comorbidity, n (%)
Hypertension 10 (18.2) 2 (11.1)
Diabetes mellitus 5 (9.1) 0 (0.0)
Old cerebrovascular accident 2 (3.6) 0 (0.0)
Arrythmia 1 (1.8) 0 (0.0)
Other cardiac disease 3 (5.5) 0 (0.0)
Dyslipidemia 11 (20.0) 4 (22.2)
Fatty liver 2 (3.6) 1 (5.6)
History of malignant disease 2 (3.6) 0 (0.0)
Heartburn
Frequency, /week, mean ± SD 4.8 ± 4.5 18.4 ± 27.4
Duration, month, mean ± SD 22.5 ± 58.2 5.7 ± 4.6
Regurgitation
Frequency, /week, mean ± SD 3.6 ± 3.4 22.1 ± 36.5
Duration, month, mean ± SD 23.6 ± 59.8 5.2 ± 4.4
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respectively. Baseline characteristics of participants who were assessed for biologic markers and microbiomes 
are also shown in Table 1.
Treatment response. At week four, the complete and partial response rates were 54.5% and 23.6%, respec-
tively, for heartburn and 50.9% and 34.5%, respectively, for regurgitation (Fig. 1). The complete response tended 
to increase for both heartburn and regurgitation at week eight compared to that at week four (heartburn at week 
eight: complete, 60.0%; partial, 32.7%; regurgitation at week eight: complete, 61.8%; partial, 29.1%).
Table 2 shows the data for patient adherence to PPIs and changes in symptom scores obtained using the 
patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) and the hospital anxiety and 
depression scale (HAD) questionnaires. The PAGI-SYM score, based on a six-point Likert scale (from zero to 
five), was 1.85 ± 1.43 for heartburn and 2.18 ± 1.45 for regurgitation at baseline, both of which decreased at week 
four (P < 0.001 for both). The adherence rate was 97.5 ± 5.2% for the first four weeks, and 96.8% ± 5.8% for the 
next four weeks (between week four and week eight). The PAGI-SYM score for heartburn at week eight was lower 
than that at baseline; however, there was no significant difference between the scores at week four and week 
eight (week four, 0.65 ± 0.93; week eight, 0.54 ± 0.80; P = 0.381). The PAGI-SYM score for regurgitation at week 
eight further decreased compared to that at week four (week four, 0.73 ± 0.93; week eight, 0.50 ± 0.38; P = 0.035).
Figure 1.  Proton pump inhibitor treatment response for typical gastroesophageal reflux diseases. At week four, 
the complete and partial response rates for heartburn were 54.5% and 23.6%, respectively, and the complete and 
partial response rates for regurgitation were 50.9% and 34.5%, respectively. After PPI treatment for eight weeks, 
the complete response tended to increase for both heartburn and regurgitation compared to those at week four. 
PPI, proton pump inhibitor.
Table 2.  Changes in symptom scores after proton pump inhibitor administration. PAGI-SYM, HAD, 
and adherence rate were presented as mean with standard deviation. Adherence rate was defined as the 
number of drugs taken divided by the number of drugs to be taken. PAGI-SYM, patient assessment of upper 
gastrointestinal symptom severity index; HAD, hospital anxiety and depression scale.
Variable Baseline Week 4 P-value (vs. baseline) Week 8 P-value (vs. baseline) P-value (vs. week 4)
PAGI-SYM (0–5)
Heartburn/regurgitation
 Heartburn 1.85 ± 1.43 0.65 ± 0.93  < 0.001 0.54 ± 0.80  < 0.001 0.381
 Regurgitation 2.18 ± 1.45 0.73 ± 0.93  < 0.001 0.50 ± 0.38  < 0.001 0.035
Nausea/vomiting 0.97 ± 1.09 0.32 ± 0.52  < 0.001 0.23 ± 0.66  < 0.001 0.396
Early satiety 1.49 ± 1.03 0.84 ± 0.72  < 0.001 0.59 ± 0.64  < 0.001 0.001
Bloating 1.35 ± 1.28 0.74 ± 0.91  < 0.001 0.48 ± 0.85  < 0.001 0.018
Upper abdominal pain 1.72 ± 1.46 0.76 ± 1.13  < 0.001 0.56 ± 0.85  < 0.001 0.166
Lower abdominal pain 0.85 ± 1.21 0.60 ± 1.00 0.069 0.45 ± 0.74 0.004 0.107
HAD (0–3)
 Anxiety 0.76 ± 0.49 0.57 ± 0.42  < 0.001 0.50 ± 0.38  < 0.001 0.038
 Depression 0.81 ± 0.44 0.67 ± 0.46 0.003 0.58 ± 0.44  < 0.001 0.019
Adherence rate (%) 97.5 ± 5.2 96.8 ± 5.8 0.435
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PAGI-SYM scores for nausea/vomiting, early satiety, bloating, upper abdominal pain, and lower abdominal 
pain decreased at week four compared to those at baseline, and the scores for early satiety and bloating further 
decreased at week eight compared to those at week four. Additionally, HAD scores for both anxiety and depres-
sion decreased from baseline to week four, as well as from week four to week eight.
Biologic markers in esophageal mucosa. Real-time quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) was performed to assess the expression of mRNAs encoding biologic markers in 18 
patients who received upper gastrointestinal endoscopy during screening. The complete and partial response 
rates for eight weeks of PPI therapy among these 18 patients were 55.6% and 38.9%, respectively, for heartburn, 
and 50.0% and 33.3%, respectively, for regurgitation (Table S1).
Figure 2 shows changes in the expression of biologic markers in the esophageal mucosa after PPI therapy for 
eight weeks. Of the 15 tested markers, the expression of mRNAs encoding IL-6, IL-8, NF-κB, TNF-α, CLDN-1, 
and TRPV1 showed statistically significant decreases after PPI administration. All nine inflammatory makers 
except IL-1β showed a tendency for decreased expression after PPI administration. In the subgroup analysis 
between patients with complete response for both heartburn and regurgitation (n = 8) and those with partial 
response or non-response (n = 10), no difference in the expression of biologic markers was observed except for 
Figure 2.  Changes in the expression of biologic markers in the esophageal mucosa after eight weeks of 
proton pump inhibitor administration. Nine inflammatory markers (IFN-γ, IL-1β, IL-6, IL-8, IL-10, MCP1, 
NF-κB, RANTES, and TNF-α), four permeability markers (OCLN, ZO-1, CLDN-1, and CLDN-4), and two 
hypersensitivity markers (ASIC-3 and TRPV1) were assessed. The expression levels of IL-6, IL-8, NF-κB, TNF-α, 
CLDN-1, and TRPV1 showed statistically significant decrease after PPI administration. All nine inflammatory 
markers, except IL-1β, showed a tendency for decreased expression after PPI administration. Lines indicate the 
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MCP1 [median (interquartile range): complete response 0.008 (0.005–0.009), partial or non-response 0.004 
(0.002–0.005); P = 0.016].
Oropharyngeal and esophageal microbiomes. Oropharyngeal and esophageal microbiome analyses 
were performed in the 18 patients who underwent upper gastrointestinal endoscopy; however, several patients 
were excluded due to insufficient amounts of extracted DNA for microbiome analyses (n = 1 excluded for week 
eight oropharyngeal microbiome analysis, n = 6 excluded for baseline esophageal microbiome analysis, and n = 8 
excluded for week eight esophageal microbiome analysis).
The number of operational taxonomic units (OTUs) and the Chao1 index tended to be lower in the esophagus 
than in the oropharynx at baseline as well as at week eight; however, there was no significant difference, except in 
the Chao1 index, between oropharynx and esophagus at week eight (Figure S1). Shannon and inverse Simpson 
indices were similar regardless of organ (oropharynx vs. esophagus) and time-point (baseline vs. week eight).
Figure 3 demonstrates the compositions of the microbiome by organ and time-point. At the phylum level, the 
common bacterial taxa were Firmicutes, Proteobacteria, and Bacteroidetes regardless of organ and time-point. At 
the genus level, Streptococcus, Haemophilus, Prevotella, Veillonella, Neisseria, and Granulicatella were commonly 
identified. As shown in Fig. 4, at baseline, the overall composition of the oropharyngeal microbiome was differ-
ent from that of the esophageal microbiome (P = 0.004). On the contrary, at week eight, there was no significant 
difference between the oropharyngeal microbiome and the esophageal microbiome (P = 0.140). Additionally, no 
significant difference was identified between the baseline and week eight in the oropharyngeal microbiome as 
well as in the esophageal microbiome (P = 0.334 and P = 0.920, respectively; Figure S2).
As shown in Figure S3, the linear discriminant analysis demonstrated the relatively abundant bacterial taxa 
in each group. At baseline, Enterobacteriaceae and Chitinophagaceae were more abundant whereas unclassified 
Clostridiales Family XIII and Methylobacteriaceae were less abundant in the esophageal microbiome than in the 
oropharyngeal microbiome. At week eight, there was no difference in the relative abundance of bacterial taxa in 
the esophageal microbiome and those in the oropharyngeal microbiome.
Correlations between the expression of biologic markers and the relative abundance of bacte‑
rial taxa. Figure 5 shows the correlation coefficients between the expression of biologic markers and the rela-
tive abundance of bacterial taxa at the phylum level. Overall, the correlation was commonly observed between 
some bacterial taxa and other bacterial taxa. However, several biologic markers, including NF-κB, IL-1β, and 
IL-8, were also correlated with bacterial taxa [NF-κB and esophageal Fusobacteria: correlation coefficient 
(γ) = 0.68, P = 0.032; IL-1β and oropharyngeal Tenericutes: γ = 0.64, P = 0.048; IL-8 and esophageal Spirochaetes: 
γ = 0.72, P = 0.018].
Discussion
In the current study, we evaluated the treatment response to 20 mg of esomeprazole in patients with NERD. As 
previously shown, NERD is less likely to respond to PPI  therapy7,20,21. Our study also revealed the non-response 
rate of PPI administration for four weeks to be 21.8% for heartburn and 14.5% for regurgitation. These results 
were relatively higher compared to the results of the large-scale study on GERD (including erosive esophagitis) 
conducted by Eggleston et al.22 In that study, the non-response rate was 9.8% for heartburn and 12.4% for regur-
gitation after four weeks of PPI treatment (20 mg of esomeprazole, which is the same dose as that used in our 
study). The complete response rate in our study was 54.5% for heartburn and 50.9% for regurgitation, whereas in 
the study by Eggleston et al. it was 60.6% for heartburn and 60.1% for regurgitation. The relatively lower response 
rate in our study than that reported by Eggleston et al. may be due to the inclusion of only patients with NERD.
However, the treatment response rate may be increased by prolonged PPI therapy. In our study, the complete 
response rate at week eight was 60.0% for heartburn and 61.8% for regurgitation, and the non-response rate at 
week eight was 7.3% for heartburn and 9.1% for regurgitation. These eight-week response rates in this study were 
similar to the four-week response rates in the study by Eggleston et al., which included both erosive esophagitis 
and NERD patients. Even in NERD patients, typical symptoms can be effectively controlled by prolonged PPI 
therapy.
One of the main causes of treatment failure in patients who were presumably diagnosed with NERD is an 
incorrect diagnosis. Some patients diagnosed with NERD may actually have esophageal hypersensitivity or 
functional heartburn, rather than true  NERD20. In the current study, we included patients who showed typical 
GERD symptoms with high frequency and a relatively long duration. The participants manifested symptoms 
other than heartburn/regurgitation, such as nausea/vomiting or bloating, with less severity. Although we did 
not perform a 24 h-ambulatory pH monitoring, we believe that patients with true NERD, rather than esopha-
geal hypersensitivity or functional heartburn, were mainly included in our study. It should be kept in mind that 
prolonged PPI therapy does not always guarantee successful symptom control in patients who are presumably 
diagnosed with NERD.
In our study, we also aimed to evaluate changes in biologic markers, which are already known to be related 
to reflux esophagitis of the esophageal mucosa. Among inflammatory, permeability, and hypersensitivity mark-
ers, inflammatory cytokines were mostly reduced by PPI therapy. All inflammatory biomarkers, except IL-1β, 
decreased after PPI administration, with moderate amplitudes. In our previous study, IL-1β expression did not 
show any significant difference when ilaprazole, a new class of gastric acid secretion inhibitors, was administered 
to NERD  patients23. Among the decreased inflammatory cytokines, the most notable one was NF-κB, which is a 
pleiotropic regulator of the inducible expression of several  genes24–26. Constitutively activated NF-κB is commonly 
identified in various tumors and cancer cell  lines27–30. Several studies reported that it regulates cell prolifera-
tion, tumor development, and cell  transformation25,31. The expression of NF-κB gradually increases as disease 
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progressed from Barrett’s esophagus to esophageal  adenocarcinoma24,32,33. In our study, the esophageal expres-
sion of NF-κB in patients with NERD was significantly reduced after eight weeks of treatment. Acid suppression 
by PPI therapy not only improved typical GERD symptoms but also reduced the expression of inflammatory 
cytokines. Additionally, the expression of NF-κB was significantly correlated with the abundance of esophageal 
Fusobacteria. Although causality cannot be concluded between Fusobacteria and esophageal inflammation, this 
may be an interesting finding because Fusobacteria has been known to be related to gingivitis, periodontitis, 
esophagitis, and esophageal  cancer34,35.
In addition to NF-κB, we showed that the expression levels of IL-6 and IL-8 reduced after PPI therapy. It is 
known that NF-κB upregulates various cytokines, including IL-6, leading to an increase in STAT3  signalling33. 
Another study demonstrated that both IL-6 and activated STAT3 were increased in transformed Barrett’s  cells33,36. 
IL-8 is a potent activator of NF-κB and is commonly found in esophageal  adenocarcinoma24,37. Recently, Dunbar 
et al. reported that reflux esophagitis may be caused by pro-inflammatory cytokines rather than chemical injury 
by gastric acid, bile, and  pepsin38. PPI therapy has a direct anti-inflammatory effect, independent of its effect on 
Figure 3.  Microbial compositions according to the organ (oropharynx vs. esophagus) and time-point (baseline 
vs. week eight) at the (A) phylum level, (B) family level, and (C) genus level. At the phylum level, the common 
bacterial taxa were Firmicutes, Proteobacteria, and Bacteroidetes regardless of organ and time-point. At the 
genus level, Streptococcus, Haemophilus, Prevotella, Veillonella, Neisseria, and Granulicatella were commonly 
identified. Values in the bars represent the relative abundance of individual taxa.
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acid  secretion38. Although the mechanisms of PPI activity in NERD are not exactly known, we found that PPI 
reduced the inflammation even in NERD patients.
One of the major findings in our study is oropharyngeal and esophageal microbiomes before and after PPI 
therapy. We found that Streptococcus is the most prevalent bacterial taxon in the esophageal microbiome of 
patients with NERD. It is well known that Streptococcus is abundant in the normal as well as diseased esophagus 
(i.e., GERD or Barrett’s esophagus)35. We additionally identified Haemophilus, Prevotella, Veillonella, Neisseria, 
Figure 4.  Principal component analysis of the microbiome according to the organ (oropharynx vs. esophagus) 
at (A) baseline and (B) week eight. At baseline, the oropharynx had different microbial composition compared 
to the esophagus (P = 0.004 by the ANOSIM test). On the contrary, at week eight, the difference in microbial 
compositions between the organs (oropharynx vs. esophagus) were not identified (P = 0.140 by the ANOSIM 
test). ANOSIM, analysis of similarities.
Figure 5.  Correlations between the expression of biologic marker and the relative abundance of bacterial taxa 
(n = 10). The heatmap indicates the correlation coefficients between the expression of biologic markers and the 
relative abundance of bacterial taxa at the phylum level. Only statistically significant correlations are presented 
in this heatmap. The correlation was more common between bacterial taxa and other bacterial taxa. NF-κB, 
IL-1β, and IL-8 were correlated with esophageal Fusobacteria (γ = 0.68, P = 0.032), oropharyngeal Tenericutes 
(γ = 0.64, P = 0.048), and esophageal Spirochaetes (γ = 0.72, P = 0.018), respectively. γ, correlation coefficient.
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and Granulicatella to be common in the esophagus of patients with NERD. These bacterial taxa belong to the 
type II microbiome, which is suggested as being characteristic of patients with GERD and Barrett’s esophagus 
by Yang et al.17.
The relative abundances of major bacterial taxa were roughly similar between the oropharynx and esophagus 
of NERD patients, as shown in Fig. 3. Traditionally, microbial flora in the esophagus has been considered to be 
transient and to have translocated from the  oropharynx39. In a culture-based study, Streptococcus was the most 
commonly isolated bacteria in the esophagus, as well as the  oropharynx39. In our study, we found that the rela-
tive abundances of major bacterial taxa were similar between the oropharynx and esophagus using 16S rRNA 
gene sequencing analysis. Most bacterial taxa in the esophagus may be derived from the bacterial populations 
in the oropharynx even in patients with NERD. Although the abundances of major bacterial taxa seem to be 
similar between the oropharynx and esophagus, the PCA plot for the baseline microbiome demonstrated that the 
composition of esophageal microbiome was significantly distinguished from that of oropharyngeal microbiome 
as shown in Fig. 4A. The relative abundances of minor bacterial taxa at the genus level (designated as “others” in 
Fig. 3C) was 14.4% for the oropharynx and 22.4% for the esophagus. After PPI therapy, however, there was no 
significant difference in microbial composition between the oropharynx and esophagus. These findings implied 
that the relative abundances of minor bacterial taxa in the esophagus of patients with NERD may depend 
on acid reflux and can be resolved by PPI therapy. These minor bacterial taxa included Enterobacteriaceae, 
Chitinophagaceae, unclassified Clostridiales Family XIII, and Methylobacteriaceae as was shown by the linear 
discriminant analysis. However, these findings should be cautiously interpreted because the microbial composi-
tions did not significantly differ between the baseline and week eight in each organ (oropharynx or esophagus).
This is the first study to evaluate the treatment response and changes in the expression of biologic markers 
and microbial compositions after PPI therapy in patients with NERD. Nevertheless, the current study has several 
limitations. First, the sample size of the study was relatively small, and only 18 patients were included in the 
analyses of biologic markers and microbiomes, which were secondary endpoints of our study. Therefore, results 
of biologic markers and microbial compositions should be cautiously interpreted. Second, the diagnosis of NERD 
was not confirmed by 24 h-ambulatory pH monitoring. Therefore, patients with esophageal hypersensitivity or 
functional heartburn rather than true NERD might be included, which is a common limitation in studies similar 
to this study. However, NERD is commonly diagnosed and treated without pH monitoring in the clinical practice. 
To reflect the real-world situation, we included patients diagnosed with NERD without pH monitoring. Third, the 
amount of extracted DNA was insufficient to analyze the microbiome in several esophageal samples although we 
obtained two biopsy samples for microbiome analysis from all candidates. This may be due to lower abundance 
of the esophageal microbiome in comparison to that in other environments, such as the large intestine. In our 
experience, enough DNA can be extracted from four stomach biopsy  samples40. In subsequent studies on the 
esophageal microbiome, we will consider obtaining more than two pieces of biopsy samples for adequate analy-
sis. Fourth, our study population did not include healthy individuals. As a matter of fact, we only compared the 
GERD symptom scores, expression levels of biologic markers, and microbial compositions between two differ-
ent time points (or between organs in the microbiome analysis). Therefore, it is difficult to determine whether 
the treatment response and changes in biologic marker expression and microbial composition are entirely due 
to PPI therapy. The patients with erosive reflux disease were not included in this study. Further studies on dif-
ferent disease status (NERD vs. healthy or erosive reflux disease) may be required. Fifth, dietary intake was not 
controlled in our study, which might impact the microbial compositions in the oropharynx and esophagus. If 
the dietary intake had been controlled, a more definitive conclusion may have been reached.
Despite these limitations, our study provides a better understanding of the efficacy of PPI therapy as well as 
data on biologic marker expression after administration of PPIs, together with analysis of oropharyngeal and 
esophageal microbiomes in patients with NERD. Half-dose PPI therapy for eight weeks was effective for typical 
GERD symptom control. PPI therapy also reduced the expression of inflammatory cytokines, including IL-6, 
IL-8, and NF-κB, in the esophagus. Although major bacterial taxa in the esophagus, including Streptococcus, 
Haemophilus, Prevotella, Veillonella, Neisseria, and Granulicatella, were similar to those in the oropharynx, the 
overall microbial composition was different between oropharynx and esophagus before PPI therapy in patients 
with NERD. However, impact of PPI on the oropharyngeal or esophageal microbiome was not identified in this 
study. The microbial compositions in the oropharynx and esophagus were not affected by PPI therapy. Impact 
of PPI on the microbiome in patients with NERD should be more investigated in future studies.
Methods
Study design. Our trial was a prospective, multicenter, single-arm study with an eight-week duration 
(ClinicalTrials.gov NO. NCT03436914). We included patients aged 19 years or older who had been diagnosed 
with NERD based on the presence of typical symptoms, including heartburn, regurgitation, and the absence of 
esophageal erosion in the study. Patients who experienced heartburn or regurgitation at least ≥ one day/week for 
more than three months before screening were included. The exclusion criteria were as follows: (1) active peptic 
ulcer diseases, (2) previous upper gastrointestinal surgery, and (3) pregnancy or breast-feeding. If patients were 
receiving antibiotics, acid-suppressive agents, probiotics, prokinetics, mucoprotective agents, aspirin, nonsteroi-
dal anti-inflammatory drugs, or corticosteroids, their medications had to be stopped for at least four weeks 
before starting the treatment. Written informed consent was obtained from all participants before screening. 
The Institutional Review Board of the seven participating hospitals in Korea (Severance Hospital, Hanyang 
University Guri Hospital, Kangdong Sacred Heart Hospital, Incheon St Mary’s Hospital, Chungnam National 
University Hospital, Chung-Ang University Hospital, Korea University Guro Hospital) approved this study. All 
methods were carried out in accordance with relevant guidelines and regulations.
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Patients who underwent upper gastrointestinal endoscopy within six months of enrolment and who were 
diagnosed with NERD were exempted from the screening endoscopy. They received 20 mg of esomeprazole 
(Esomezol, Hanmi Pharm. Co., Ltd., Seoul, Korea) for eight weeks. To evaluate the treatment response of PPIs 
in NERD, the PAGI-SYM and the HAD questionnaires were completed at baseline (week zero), week four, and 
week  eight41,42.
If patients had not been diagnosed with NERD and/or had not undergone upper gastrointestinal endoscopy 
within six months of enrolment, they underwent screening with upper gastrointestinal endoscopy to rule out 
organic diseases and erosive esophagitis. Each participant received an oropharyngeal swab to assess the oro-
pharyngeal microbiome, followed by upper gastrointestinal endoscopy. If esophageal erosion was not found upon 
endoscopy and the participant met other inclusion criteria, four pieces of esophageal mucosa were obtained by 
a biopsy at 3 cm above the gastroesophageal junction to evaluate biologic markers and the microbiome (two 
for biologic marker analysis and two for microbiome analysis). Patients also received 20 mg of esomeprazole 
(Esomezol, Hanmi Pharm. Co., Ltd., Seoul, Korea) for eight weeks and questionnaires (PAGI-SYM and HAD) 
at baseline (week zero), week four, and week eight. At the end of the eight weeks, the participants received oro-
pharyngeal swabs and upper endoscopy to obtain four additional pieces of esophageal mucosa.
Study endpoint. The primary endpoint was the treatment response in terms of typical GERD symptoms—
heartburn and regurgitation. The secondary endpoints were as follows: (1) the treatment response in terms of 
other symptoms, including nausea/vomiting, early satiety, bloating, upper and lower abdominal pain, anxiety, 
and depression; (2) the expression of biologic markers, and (3) the compositions of oropharyngeal and esopha-
geal microbiomes.
Definition. Treatment responses of typical GERD symptoms were classified into three categories—complete 
response, partial response, and non-response, based on the PAGI-SYM scores. If the PAGI-SYM score reached 
zero points, the treatment response was regarded as a complete response. If PAGI-SYM score after PPI adminis-
tration was lower compared to that at baseline without reaching zero, the treatment response was regarded as a 
partial response. Non-response was defined as a lack of improvement of the PAGI-SYM score after PPI admin-
istration. The patient’s adherence rate to the study medication was defined as the number of drugs taken divided 
by the number of drugs to be taken. Body mass index (BMI) was calculated as the measured weight (kg) divided 
by the square of the height (/m2), and obesity was defined as BMI ≥ 25 kg/m2, which is the proposed cut-off value 
for the diagnosis of obesity in  Asians43.
Evaluation of biologic markers. To evaluate biologic markers in the esophageal mucosa, the biopsy sam-
ples were immediately stored in RNA later (Invitrogen, Carlsbad, CA, USA) at the bedside. Fresh tissues in 
RNA later were maintained at − 80 °C until the measurement of messenger RNA (mRNA) levels. All the samples 
obtained at different institutes were collected at Severance hospital. RNA was extracted from the esophageal 
mucosal samples as described in our previous  study23,44.
For complementary DNA synthesis, total RNA was reverse transcribed using SuperScript II (Invitrogen) 
following the manufacturer’s protocol. qRT-PCR was performed using iQ SYBR Green Supermix (Applied Bio-
systems Inc., Carlsbad, CA, USA) and a Roche Light Cycler480 Real-Time PCR System (Idaho Technology Inc., 
Salt Lake City, UT, USA).
The fifteen biologic markers evaluated in this study include inflammatory (IFN-γ, IL-1β, IL-6, IL-8, IL-10, 
MCP1, NF-κB, RANTES, and TNF-α), permeability (OCLN, ZO-1, CLDN-1, and CLDN-4), and hypersensitiv-
ity (ASIC-3 and TRPV1) markers. The expression of biologic markers was calculated using the  2-ΔΔCT method, 
with the expression level of glyceraldehyde-3-phosphate dehydrogenase used for normalization. The primer 
sequences for qPCR are listed in Table S2.
Evaluation of the oropharyngeal and esophageal microbiome. DNA extraction from the oro-
pharyngeal and esophageal mucosal samples was performed as described  previously40. Next, we performed 16S 
rRNA gene sequencing for identifying microbiome composition. DNA quantification and quality assessment 
were performed using PicoGreen and Nanodrop, respectively. Input gDNA was amplified using 16S V3–V4 
primers. To add multiplexing indices and Illumina sequencing adapters, limited‐cycle amplification was per-
formed. We normalized and pooled the final products using PicoGreen. The library size was verified using 
TapeStation DNA screentape D1000 (Agilent). We subsequently sequenced DNA using the MiSeq platform 
(Illumina, San Diego, CA, USA), and the data were analyzed using QIIME version 1.9.045. Low-quality reads 
with incorrect primer sequences or ambiguous bases were excluded. Using the unique nucleotide barcodes, the 
reads were classified into groups. The taxonomic assignment was performed based on a 97% similarity with the 
GreenGenes database (version 13.5) using QIIME. The DNA sequences were deposited in the National Center 
for Biotechnology Information Short Read Archive under the Accession No. PRJNA655630.
Microbiome compositions were further evaluated using principal component analysis (PCA) plots and com-
pared using the analysis of similarities (ANOSIM) test. Differential abundant features of relative abundances of 
bacterial taxa were identified using the linear discriminant  analysis46.
Sample size calculation. The proportion of complete response was assumed to be 60% because the treat-
ment response in NERD is usually lower than that in erosive  esophagitis1,22. To detect a difference of 0.2 using a 
two-sided binomial test, a sample size of 49 is required at a 5% target significance level and 80% statistical power. 
Considering a 20% dropout rate, we planned to recruit 62 patients in this study.
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Statistical analysis. Continuous and categorical variables were presented as mean with standard devia-
tion and frequency with percentage, respectively. The expression of biologic markers between any two time 
points was compared by the Wilcoxon singed-rank test. Because paired data were unavailable due to miss-
ing values in some patients, OTUs and microbial diversity index between any two time points were compared 
using the Mann–Whitney U test. The expression of biologic markers and microbial diversity index between 
patient subgroups were also compared by the Mann–Whitney U test. The correlations between the expression 
of biologic markers and the relative abundance of bacterial taxa were evaluated using the Pearson correlation 
test. All P-values were two-tailed, and P-values of < 0.05 were considered statistically significant. All statistical 
procedures were conducted using R (version 3.6.2; R Foundation for Statistical Computing, Vienna, Austria), 
except for linear discriminant analysis, which was performed using Galaxy, an open, web-based platform for 
computational biomedical research (https ://hutte nhowe r.sph.harva rd.edu/galax y).
Received: 24 February 2020; Accepted: 18 August 2020
References
 1. Fass, R. et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in 
patients with non-erosive reflux disease. Aliment Pharmacol. Ther. 29, 1261–1272 (2009).
 2. Khan, Z. et al. On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild 
erosive esophagitis: a systematic review and meta-analysis. Gastroenterol. Res. Pract. 2018, 6417526 (2018).
 3. Hershcovici, T. & Fass, R. Nonerosive Reflux Disease (NERD)—an update. J. Neurogastroenterol. Motil. 16, 8–21 (2010).
 4. Bayerdorffer, E. et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole 
in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 16, 48 (2016).
 5. Moayyedi, P. & Talley, N. J. Gastro-oesophageal reflux disease. Lancet 367, 2086–2100 (2006).
 6. Sigterman, K. E. et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gas-
tro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst. Rev. https ://doi.
org/10.1002/14651 858.CD002 095.pub5 (2013).
 7. Dean, B. B. et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin. Gastroenterol. Hepatol. 2, 656–664 
(2004).
 8. Fass, R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic 
characteristics. J. Clin. Gastroenterol. 41, 131–137 (2007).
 9. Fass, R. & Ofman, J. J. Gastroesophageal reflux disease–should we adopt a new conceptual framework?. Am. J. Gastroenterol. 97, 
1901–1909 (2002).
 10. Fass, R. Non-erosive reflux disease (NERD) and erosive esophagitis–a spectrum of disease or special entities?. Z Gastroenterol 45, 
1156–1163 (2007).
 11. Tack, J. & Pandolfino, J. E. Pathophysiology of gastroesophageal reflux disease. Gastroenterology 154, 277–288 (2018).
 12. Di Pilato, V. et al. The esophageal microbiota in health and disease. Ann. N Y Acad. Sci. 1381, 21–33 (2016).
 13. Jung, Y. S. et al. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. 
Helicobacter https ://doi.org/10.1111/hel.12389 (2017).
 14. Lauritano, D. et al. Focus on periodontal disease and colorectal carcinoma. Oral Implantol. (Rome) 10, 229–233 (2017).
 15. Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvi-
ronment. Cell Host Microbe 14, 207–215 (2013).
 16. Park, C. H. et al. Role of Fusobacteria in the serrated pathway of colorectal carcinogenesis. Sci. Rep. 6, 25271 (2016).
 17. Yang, L. et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. 
Gastroenterology 137, 588–597 (2009).
 18. Gall, A. et al. Bacterial composition of the human upper gastrointestinal tract microbiome is dynamic and associated with genomic 
instability in a Barrett’s Esophagus cohort. PLoS ONE 10, e0129055 (2015).
 19. Deshpande, N. P. et al. Signatures within the esophageal microbiome are associated with host genetics, age, and disease. Microbiome 
6, 227 (2018).
 20. Fock, K. M. et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory 
reflux disease and Barrett’s oesophagus. Gut 65, 1402–1415 (2016).
 21. Zschau, N. B. et al. Gastroesophageal reflux disease after diagnostic endoscopy in the clinical setting. World J. Gastroenterol. 19, 
2514–2520 (2013).
 22. Eggleston, A. et al. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care–prospective randomized 
comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol. Ther. 29, 967–978 (2009).
 23. Song, I. J., Kim, H. K., Lee, N. K. & Lee, S. K. Prospective single arm study on the effect of ilaprazole in patients with heartburn 
but no reflux esophagitis. Yonsei Med. J. 59, 951–959 (2018).
 24. Abdel-Latif, M. M. et al. Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression fol-
lowing neoadjuvant chemoradiotherapy. Dis. Esophagus 18, 246–252 (2005).
 25. Baeuerle, P. A. & Henkel, T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12, 141–179 
(1994).
 26. Kopp, E. B. & Ghosh, S. NF-kappa B and rel proteins in innate immunity. Adv. Immunol. 58, 1–27 (1995).
 27. Lind, D. S. et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 130, 363–369 (2001).
 28. Sovak, M. A. et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100, 
2952–2960 (1997).
 29. Mori, N. et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 93, 2360–2368 (1999).
 30. Nakshatri, H. et al. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. 
Mol. Cell Biol. 17, 3629–3639 (1997).
 31. Barnes, P. J. & Karin, M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 
336, 1066–1071 (1997).
 32. Abdel-Latif, M. M. et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett’s metaplasia, survival, and 
response to neoadjuvant chemoradiotherapy. Ann. Surg. 239, 491–500 (2004).
 33. Dvorak, K. & Dvorak, B. Role of interleukin-6 in Barrett’s esophagus pathogenesis. World J. Gastroenterol. 19, 2307–2312 (2013).
 34. Han, Y. W. Fusobacterium nucleatum: a commensal-turned pathogen. Curr. Opin. Microbiol. 23, 141–147 (2015).
11
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15154  | https://doi.org/10.1038/s41598-020-72082-8
www.nature.com/scientificreports/
 35. Park, C. H. & Lee, S. K. Exploring esophageal microbiomes in esophageal diseases: a systematic review. J. Neurogastroenterol. Motil. 
26, 171–179 (2020).
 36. Zhang, H. Y. et al. Cancer-related inflammation and Barrett’s carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance 
in transformed Barrett’s cells. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G454-460 (2011).
 37. Manna, S. K. & Ramesh, G. T. Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway. 
J. Biol. Chem. 280, 7010–7021 (2005).
 38. Dunbar, K. B. et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA 315, 2104–2112 
(2016).
 39. Gagliardi, D. et al. Microbial flora of the normal esophagus. Dis. Esophagus 11, 248–250 (1998).
 40. Park, C. H. et al. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S 
rRNA gene sequencing. Helicobacter 24, e12547 (2019).
 41. Rentz, A. M. et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity 
index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual. Life Res. 13, 1737–1749 (2004).
 42. Zigmond, A. S. & Snaith, R. P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67, 361–370 (1983).
 43. Wen, C. P. et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public 
Health Nutr. 12, 497–506 (2009).
 44. Youn, Y. H. et al. Long noncoding RNA N-BLR upregulates the migration and invasion of gastric adenocarcinoma. Gut Liver 13, 
421–429 (2019).
 45. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).
 46. Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).
Acknowledgements
This study was performed by the GERD Research Group of the Korean Society of Neurogastroenterology and 
Motility. This study was supported by a research grant from the Hanmi Pharmaceutical company. The Hanmi 
Pharmaceutical company was not involved in the design of the study, its conduction and analysis, or the inter-
pretation of study results.
Author contributions
Conception and design: S.K.L., Acquisition of data: C.H.P., S.I.S., J.S.K., S.H.K., B.J.K., Y.J.C., S.K.L., Analysis and 
interpretation of data: C.H.P., H.J.B., J.Y., S.K.L., Statistical analysis: C.H.P., Drafting manuscript: C.H.P., S.K.L., 
Review of manuscript: All authors, Study supervision: S.K.L.
competing interests 
The authors declare no competing interests.
Additional information
Supplementary information  is available for this paper at https ://doi.org/10.1038/s4159 8-020-72082 -8.
Correspondence and requests for materials should be addressed to S.K.L.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
